PharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial Design
October 23 2015 - 9:20AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today the release of a
recorded interview with Chief Executive Officer Kenneth L. Waggoner
and Chief Operating Officer Dr. Gerald W. Crabtree that highlights
the key aspects of PharmaCyte’s new pancreatic cancer clinical
trial design.
Listen to the interview
here: http://www.stockmarketmediagroup.com/wp-content/uploads/2015/10/PharmaCyte_Biotech_CEO_Interview.mp3
The interview walks the audience through
PharmaCyte’s last three press releases that announce the change in
its clinical trial design. In the interview, PharmaCyte’s Chief
Executive Officer and Chief Operating Officer discuss PharmaCyte’s
efforts to address an unmet medical need with PharmaCyte’s
pancreatic cancer treatment, why the trial was moved to the United
States under the direction of Translational Drug Development (TD2)
and some of the specifics related to the new trial design.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage
biotechnology company focused on developing and preparing to
commercialize treatments for cancer and diabetes based upon a
proprietary cellulose-based live cell encapsulation technology
known as “Cell-in-a-Box®”. This unique and patented technology will
be used as a platform upon which treatments for several types of
cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves
encapsulating genetically modified live cells capable of converting
an inactive chemotherapy drug (ifosfamide) into its active or
“cancer-killing” form. These encapsulated live cells are placed as
close to a cancerous tumor as possible. Once implanted in a
patient, ifosfamide is then given intravenously at one-third the
normal dose. The ifosfamide is carried by the circulatory system to
where the encapsulated cells have been placed. When ifosfamide,
which is normally activated in the liver, comes in contact with the
encapsulated live cells, activation of the drug takes place at the
source of the cancer without any side effects from the
chemotherapy. This “targeted chemotherapy” has proven remarkably
effective and safe to use in past clinical trials.
In addition to developing a novel treatment for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and Type 2 insulin-dependent diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and secrete insulin at levels in proportion to
the levels of blood sugar in the human body. The encapsulation will
be done using the Cell-in-a-Box® technology.
Safe Harbor This press release may
contain forward-looking statements regarding PharmaCyte Biotech and
its future events and results that involve inherent risks and
uncertainties. The words "anticipate," "believe," "estimate,"
"expect," "intend," "plan" and similar expressions, as they relate
to PharmaCyte or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte, could cause actual results to
differ materially from those set forth in the forward-looking
statements. They include PharmaCyte's ability to continue as a
going concern, delays or unsuccessful results in preclinical and
clinical trials, flaws or defects regarding its product candidates,
changes in relevant legislation or regulatory requirements,
uncertainty of protection of PharmaCyte’s intellectual property and
PharmaCyte’s continued ability to raise capital. PharmaCyte does
not assume any obligation to update any of these forward-looking
statements.
More information about PharmaCyte can be found at
www.PharmaCyte.com. It can also be obtained by contacting Investor
Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com